Loading...
MITO logo

Stealth BioTherapeutics CorpNasdaqGM:MITO 株式レポート

時価総額 US$23.5m
株価
n/a
私の公正価値
n/a
1Y-68.0%
7D-0.1%
1D
ポートフォリオ価値
​
表示

Stealth BioTherapeutics Corp

NasdaqGM:MITO 株式レポート

時価総額：US$23.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Stealth BioTherapeutics（MITO）株式概要

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. 詳細

MITO ファンダメンタル分析
スノーフレーク・スコア
評価2/6
将来の成長0/6
過去の実績0/6
財務の健全性0/6
配当金0/6

報酬

過去5年間の収益は年間14.4%増加しました。

リスク分析

収益が 100 万ドル未満 ( $0 )

マイナスの株主資本

意味のある時価総額がありません ( $24M )

過去1年間で株主の希薄化が進んだ

+2 さらなるリスク

MITO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Stealth BioTherapeutics Corp 競合他社

価格と性能

株価の高値、安値、推移の概要Stealth BioTherapeutics
過去の株価
現在の株価US$0.32
52週高値US$1.03
52週安値US$0.16
ベータ1.46
1ヶ月の変化1.75%
3ヶ月変化3.76%
1年変化-68.00%
3年間の変化-95.86%
5年間の変化n/a
IPOからの変化-97.31%

最新ニュース

Seeking Alpha • Sep 30

Stealth Biotherapeutics chief financial officer Robert Weiskopf leaves company

Stealth BioTherapeutics (NASDAQ:MITO) said on Friday Robert Weiskopf, its chief financial officer, is leaving the company effective September 30. Weiskopf joined Stealth in 2019 following the initial public offering.
Seeking Alpha • Aug 01

Stealth BioTherapeutics shares pop ~20% premarket after co agrees to go private

Stealth BioTherapeutics (NASDAQ:MITO) on Monday said it had agreed to go private by being acquired by Morningside Venture (I) Investments, over a month after the clinical-stage biotech received the investment firm's preliminary proposal. MITO stock jumped 19.9% to $0.29 in premarket trading on the announcement. As per the terms of the deal, a consortium of investors led by Morningside for itself and on behalf of its affiliates and J. Wood Capital Advisors LLC will buy MITO for $0.03125 per share and $0.375 per ADS in an all-cash transaction. The per ADS consideration represents a 56.3% premium to Stealth's (MITO) last closing price of $0.24, and a 33.9% premium to the company's closing price of $0.28 on June 24, which was the last trading day before MITO said it had got the preliminary proposal. The Morningside led consortium intends to fund the merger through cash contributions from its members. MITO said its board had approved the deal and that the merger was expected to close during H2 this year.
Seeking Alpha • Jul 26

Stealth BioTherapeutics: A Net-Net Biopharma Going Private

This seems to be an interesting going private setup currently offering a 10% upside. Majority shareholder Morningside is acquiring the remaining 33% stake in a nanocap biopharmaceutical company Stealth BioTherapeutics. The buyer has indicated that it wants to complete the transaction swiftly and without broad due diligence. Offer cancellation risk seems to be low as the company is an advanced-stage biopharma that is currently trading below net cash while the buyer seems reputable and controls the company. On June 24, Morningside Venture Investments (MVIL) issued a non-binding proposal to acquire the remaining outstanding shares of a clinical-stage biopharmaceutical Stealth BioTherapeutics (MITO). MVIL already has a 67% stake in the company. The offer is $0.313 per ADS or $0.263 after deducting ADS cancellation fees. At current prices, this offers a 10% upside (after ADS fees). Majority-of-minority shareholder approval will not be needed while the committee of independent directors is likely to accept the deal given MVIL's influence over the company. I do not expect any regulatory scrutiny from CFIUS given MITO's size. In my view, the risks here boil down to whether MVIL can walk away from the acquisition. There are several reasons why offer withdrawal seems unlikely: MITO's key phase 3 drug for Barth Syndrome seems to have a good chance of being approved by the FDA despite its rejection in October 2021. The buyer seems to be a reputable Chinese PE/VC firm and already has full control over MITO. According to the acquisition proposal, MVIL is willing complete the transaction with a "superior degree of speed" and without broad due diligence which could point to a quick buyout timeline. MITO's stock price is currently below its most recently reported net cash levels ($0.27/ADS). However, the company is burning cash at a rapid pace - the latest estimate is that the company has enough cash to fund operating expenses into Q4'22. Having said that, offer withdrawal from the Chinese company remains a risk, particularly given non-binding nature of the proposal. In my experience, non-binding takeover offers from Chinese companies generally have a noticeably lower closing rate than binding proposals. Investors should also be aware that there is a possibility that the Chinese government interrupts the payment of funds to foreign shareholders if the merger closes. MITO MITO is a ~$16m market cap clinical-stage biopharma that was founded in 2006 and IPO'ed in 2019. The company is involved in mitochondrial medicine discovery, development and commercialization. The share price has continued to decline since going public and now MITO trades close to an all-time low. This can be attributed to a couple of the company's operational failures: In 2019, MITO failed a phase 3 drug trial for a primary mitochondrial myopathy ((PNM)) drug. This was a key reason behind the 75%+ share price plunge in Dec'19. In May 2022, the company failed a phase 2 trial for elamipretide treatment for blind people. In July 2022 (already after the non-binding offer announcement) - shares sold off 15% on 5x heavier volume upon receipt of NASDAQ non-compliance warning - unlikely to be an issue while the current transaction is pending. Since the 2019 failure, the company's most advanced drug has been elamipretide for treatment of Barth Syndrome. It's currently in its Phase 3 trial. MITO has sought FDA approval for the drug since 2021. However, last fall, the FDA declined to review MITO's NDA (new drug application) as it lacked additional controlled data. The FDA recommended designing a new clinical trial instead of using historical medical records of patients as control group data. Recently, however, the drug was granted a pre-NDA meeting. Reportedly, MITO will present new clinical data collected over 3.5 years, however, it will come from the same open-label extension of the ongoing phase 2/3 study and not a new trial. The FDA has previously said that an open-label extension study would not provide enough evidence to support an NDA. However, there are several reasons to expect the FDA to eventually approve the drug: The original application showed that trial goals were met - the problem was that the data was compared to historical medical records. Nevertheless, this is encouraging and likely shows the drug's efficacy. The company has also emphasized that the trial results have been "durable" across all patients. Barth Syndrome is an ultra-rare disease - only around 130 individuals in the US have the condition. For this reason, a new clinical trial is inherently hard to design and carry out. MITO has also stated that the FDA itself did not identify a suitable trial design. BridgeBio Pharma's first FDA approval for a rare disease in early 2021 appears to be a similar case. The clinical trial relied on the same design as MITO's - historical medical records were used as control data. MITO has openly said that it did not expect the first NDA to be approved but was rather pushed by a community of Barth Syndrome advocates. The fact that now MITO has new data is encouraging. The drug for Barth Syndrome has already received orphan drug, rare pediatric and fast track designations from the FDA, showing its uniqueness and essentiality for some part of the population. There are no FDA-approved drugs for the disease and other treatments are potentially years away. The meeting is expected in Q3'22. Overall, FDA approval is far from guaranteed but it is clearly a high-potential phase 3 drug and probably explains why the controlling shareholder wants to cash out minority shareholders before the expected approval.

Recent updates

Seeking Alpha • Sep 30

Stealth Biotherapeutics chief financial officer Robert Weiskopf leaves company

Stealth BioTherapeutics (NASDAQ:MITO) said on Friday Robert Weiskopf, its chief financial officer, is leaving the company effective September 30. Weiskopf joined Stealth in 2019 following the initial public offering.
Seeking Alpha • Aug 01

Stealth BioTherapeutics shares pop ~20% premarket after co agrees to go private

Stealth BioTherapeutics (NASDAQ:MITO) on Monday said it had agreed to go private by being acquired by Morningside Venture (I) Investments, over a month after the clinical-stage biotech received the investment firm's preliminary proposal. MITO stock jumped 19.9% to $0.29 in premarket trading on the announcement. As per the terms of the deal, a consortium of investors led by Morningside for itself and on behalf of its affiliates and J. Wood Capital Advisors LLC will buy MITO for $0.03125 per share and $0.375 per ADS in an all-cash transaction. The per ADS consideration represents a 56.3% premium to Stealth's (MITO) last closing price of $0.24, and a 33.9% premium to the company's closing price of $0.28 on June 24, which was the last trading day before MITO said it had got the preliminary proposal. The Morningside led consortium intends to fund the merger through cash contributions from its members. MITO said its board had approved the deal and that the merger was expected to close during H2 this year.
Seeking Alpha • Jul 26

Stealth BioTherapeutics: A Net-Net Biopharma Going Private

This seems to be an interesting going private setup currently offering a 10% upside. Majority shareholder Morningside is acquiring the remaining 33% stake in a nanocap biopharmaceutical company Stealth BioTherapeutics. The buyer has indicated that it wants to complete the transaction swiftly and without broad due diligence. Offer cancellation risk seems to be low as the company is an advanced-stage biopharma that is currently trading below net cash while the buyer seems reputable and controls the company. On June 24, Morningside Venture Investments (MVIL) issued a non-binding proposal to acquire the remaining outstanding shares of a clinical-stage biopharmaceutical Stealth BioTherapeutics (MITO). MVIL already has a 67% stake in the company. The offer is $0.313 per ADS or $0.263 after deducting ADS cancellation fees. At current prices, this offers a 10% upside (after ADS fees). Majority-of-minority shareholder approval will not be needed while the committee of independent directors is likely to accept the deal given MVIL's influence over the company. I do not expect any regulatory scrutiny from CFIUS given MITO's size. In my view, the risks here boil down to whether MVIL can walk away from the acquisition. There are several reasons why offer withdrawal seems unlikely: MITO's key phase 3 drug for Barth Syndrome seems to have a good chance of being approved by the FDA despite its rejection in October 2021. The buyer seems to be a reputable Chinese PE/VC firm and already has full control over MITO. According to the acquisition proposal, MVIL is willing complete the transaction with a "superior degree of speed" and without broad due diligence which could point to a quick buyout timeline. MITO's stock price is currently below its most recently reported net cash levels ($0.27/ADS). However, the company is burning cash at a rapid pace - the latest estimate is that the company has enough cash to fund operating expenses into Q4'22. Having said that, offer withdrawal from the Chinese company remains a risk, particularly given non-binding nature of the proposal. In my experience, non-binding takeover offers from Chinese companies generally have a noticeably lower closing rate than binding proposals. Investors should also be aware that there is a possibility that the Chinese government interrupts the payment of funds to foreign shareholders if the merger closes. MITO MITO is a ~$16m market cap clinical-stage biopharma that was founded in 2006 and IPO'ed in 2019. The company is involved in mitochondrial medicine discovery, development and commercialization. The share price has continued to decline since going public and now MITO trades close to an all-time low. This can be attributed to a couple of the company's operational failures: In 2019, MITO failed a phase 3 drug trial for a primary mitochondrial myopathy ((PNM)) drug. This was a key reason behind the 75%+ share price plunge in Dec'19. In May 2022, the company failed a phase 2 trial for elamipretide treatment for blind people. In July 2022 (already after the non-binding offer announcement) - shares sold off 15% on 5x heavier volume upon receipt of NASDAQ non-compliance warning - unlikely to be an issue while the current transaction is pending. Since the 2019 failure, the company's most advanced drug has been elamipretide for treatment of Barth Syndrome. It's currently in its Phase 3 trial. MITO has sought FDA approval for the drug since 2021. However, last fall, the FDA declined to review MITO's NDA (new drug application) as it lacked additional controlled data. The FDA recommended designing a new clinical trial instead of using historical medical records of patients as control group data. Recently, however, the drug was granted a pre-NDA meeting. Reportedly, MITO will present new clinical data collected over 3.5 years, however, it will come from the same open-label extension of the ongoing phase 2/3 study and not a new trial. The FDA has previously said that an open-label extension study would not provide enough evidence to support an NDA. However, there are several reasons to expect the FDA to eventually approve the drug: The original application showed that trial goals were met - the problem was that the data was compared to historical medical records. Nevertheless, this is encouraging and likely shows the drug's efficacy. The company has also emphasized that the trial results have been "durable" across all patients. Barth Syndrome is an ultra-rare disease - only around 130 individuals in the US have the condition. For this reason, a new clinical trial is inherently hard to design and carry out. MITO has also stated that the FDA itself did not identify a suitable trial design. BridgeBio Pharma's first FDA approval for a rare disease in early 2021 appears to be a similar case. The clinical trial relied on the same design as MITO's - historical medical records were used as control data. MITO has openly said that it did not expect the first NDA to be approved but was rather pushed by a community of Barth Syndrome advocates. The fact that now MITO has new data is encouraging. The drug for Barth Syndrome has already received orphan drug, rare pediatric and fast track designations from the FDA, showing its uniqueness and essentiality for some part of the population. There are no FDA-approved drugs for the disease and other treatments are potentially years away. The meeting is expected in Q3'22. Overall, FDA approval is far from guaranteed but it is clearly a high-potential phase 3 drug and probably explains why the controlling shareholder wants to cash out minority shareholders before the expected approval.
Seeking Alpha • Jul 11

Stealth BioTherapeutics receives Nasdaq non-compliance receipt

A clinical-stage biotechnology company, Stealth BioTherapeutics (NASDAQ:MITO) received a letter from Nasdaq on July 7, 2022 for not meeting with minimum bid price and market value of listed securities requirements.  Company requests an appeal, trading of the company's ADS will be suspended at the opening of business on July 18, 2022. Shares +1.1% after hours
分析記事 • Dec 31

Reflecting on Stealth BioTherapeutics' (NASDAQ:MITO) Share Price Returns Over The Last Year

Stealth BioTherapeutics Corp ( NASDAQ:MITO ) shareholders should be happy to see the share price up 15% in the last...

株主還元

MITOUS BiotechsUS 市場
7D-0.1%1.0%1.3%
1Y-68.0%34.2%27.7%

業界別リターン: MITO過去 1 年間で34.2 % の収益を上げたUS Biotechs業界を下回りました。

リターン対市場: MITOは、過去 1 年間で27.7 % のリターンを上げたUS市場を下回りました。

価格変動

Is MITO's price volatile compared to industry and market?
MITO volatility
MITO Average Weekly Movement1.5%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

安定した株価: MITO 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。

時間の経過による変動: MITOの 週次ボラティリティ は、過去 1 年間で14%から2%に減少しました。

会社概要

設立従業員CEO（最高経営責任者ウェブサイト
200638Reenie McCarthywww.stealthbt.com

Stealth BioTherapeutics Corp 基礎のまとめ

Stealth BioTherapeutics の収益と売上を時価総額と比較するとどうか。
MITO 基礎統計学
時価総額US$23.54m
収益（TTM）-US$52.53m
売上高(TTM)n/a
0.0x
P/Sレシオ
-0.4x
PER（株価収益率

MITO は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
MITO 損益計算書（TTM）
収益US$0
売上原価US$0
売上総利益US$0
その他の費用US$52.53m
収益-US$52.53m

直近の収益報告

Dec 31, 2021

次回決算日

該当なし

一株当たり利益（EPS）-0.71
グロス・マージン0.00%
純利益率0.00%
有利子負債／自己資本比率-30.1%

MITO の長期的なパフォーマンスは？

過去の実績と比較を見る

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2022/11/16 08:18
終値2022/11/15 00:00
収益2021/12/31
年間収益2021/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Stealth BioTherapeutics Corp 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9

アナリスト機関
null nullBMO Capital Markets Equity Research
Charles DuncanCantor Fitzgerald & Co.
Joshua SchimmerEvercore ISI